Form 4: Acadia Pharmaceuticals EVP Mark Schneyer Reports Stock Transactions
SEC Form 4
EVP and CFO of Acadia Pharmaceuticals, Mark Schneyer, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.
Summary
- Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, reported transactions involving the company's common stock.
- On February 23, 2025, 1,353 restricted stock units vested and were converted into common stock.
- On February 24, 2025, Schneyer sold 773 shares of common stock at a price of $19.96 per share.
- The sale was mandatory and intended to cover withholding taxes related to the vesting of the restricted stock units.
- Following these transactions, Schneyer directly owns 53,882 shares of Acadia Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.
Stakeholder Impact
- The transactions have a minimal impact on stakeholders as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/23/2022 | Start date for vesting of restricted stock units in four equal annual installments |
| 02/23/2025 | 1,353 restricted stock units vested |
| 02/24/2025 | 773 shares of common stock sold at $19.96 per share |
| 02/25/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.